UroGen Pharma (URGN) vs Zenas BioPharma (ZBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
UroGen Pharma (URGN) has outperformed Zenas BioPharma (ZBIO) over the past year, gaining 113.4% versus a gain of 1.3%. UroGen Pharma is the larger company by market cap ($1.83 billion vs $1.78 billion), about 1.0 times the size, while Zenas BioPharma is growing revenue faster (+100.0% vs +21.4%). UroGen Pharma converts more of its revenue into profit, with a net margin of -139.8% versus -3777.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | URGN | ZBIO |
|---|---|---|
| Share price | $37.46 | $27.24 |
| Market cap | $1.83B | $1.78B |
| 1-day change | +1.30% | +3.81% |
| YTD return | +57.90% | -27.73% |
| 1-year return | +113.39% | +1.31% |
| 5-year return | +117.27% | — |
| Forward P/E | 13.41 | — |
| EPS (TTM) | $-1.97 | $-9.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $109.79M | $10.00M |
| Revenue growth (YoY) | +21.45% | +100.00% |
| Net income (latest FY) | $-153.49M | $-377.74M |
| Gross margin | 88.66% | — |
| Operating margin | -113.73% | -3830.57% |
| Net margin | -139.81% | -3777.37% |
| 52-week high | $50.81 | $44.60 |
| 52-week low | $15.86 | $13.50 |
| Distance from 52-week high | -26.27% | -38.92% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +60.17% | +75.77% |
| Average volume | 849.01K | 733.34K |
| Shares outstanding | 48.88M | 65.18M |
| Employees | 300 | 167 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- URGN has outperformed ZBIO by 112.1 percentage points over the past year.
- UroGen Pharma is more profitable, keeping -139.8 cents of every revenue dollar as net income versus -3777.4 cents for Zenas BioPharma.
- Zenas BioPharma grew revenue faster in its latest fiscal year (+100.00% vs +21.45%).
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
About Zenas BioPharma
ZBIO stock →Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
Health Care · Biotechnology: Pharmaceutical Preparations · 167 employees
URGN vs ZBIO FAQ
Which is bigger, UroGen Pharma or Zenas BioPharma?
UroGen Pharma (URGN) is larger, with a market capitalization of $1.83B compared with $1.78B for Zenas BioPharma (ZBIO).
Which stock has performed better over the past year, URGN or ZBIO?
URGN returned +113.39% over the past 12 months, compared with +1.31% for ZBIO (price return, excluding dividends). Past performance does not predict future results.
Are UroGen Pharma and Zenas BioPharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.